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Abstract
We have shown that ex vivo pre-conditioning of bone marrow-derived dendritic cells (DC) with low molecular weight
hyaluronan (LMW HA) induces antitumor immunity against colorectal carcinoma (CRC) in mice. In the present study we
investigated the effects of LMW HA priming on human-tumor-pulsed monocytes-derived dendritic cells (DC/TL) obtained
from healthy donors and patients with CRC. LMW HA treatment resulted in an improved maturation state of DC/TL and an
enhanced mixed leucocyte reaction activity in vivo. Importantly, pre-conditioning of DC/TL with LMW HA increased their
ability to migrate and reduced their attraction to human tumor derived supernatants. These effects were associated with
increased CCR7 expression levels in DC. Indeed, a significant increase in migratory response toward CCL21 was observed in
LMW HA primed tumor-pulsed monocyte-derived dendritic cells (DC/TL/LMW HA) when compared to LWM HA untreated
cells (DC/TL). Moreover, LMW HA priming modulated other mechanisms implicated in DC migration toward lymph nodes
such as the metalloproteinase activity. Furthermore, it also resulted in a significant reduction in DC migratory capacity
toward tumor supernatant and IL8 in vitro. Consistently, LMW HA dramatically enhanced in vivo DC recruitment to tumor-
regional lymph nodes and reduced DC migration toward tumor tissue. This study shows that LMW HA –a poorly
immunogenic molecule- represents a promising candidate to improve human DC maturation protocols in the context of
DC-based vaccines development, due to its ability to enhance their immunogenic properties as well as their migratory
capacity toward lymph nodes instead of tumors.
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Introduction
Colorectal carcinoma (CRC) is a one of the leading causes of
cancer-related death worldwide. Unfortunately, there is no
curative treatment for patients who are not amenable of surgical
resection [1]. Thus, new therapeutic strategies are needed for
advanced CRC patients and those based on mounting immune
responses against tumors might play a key role [2,3].
Dendritic cells (DC) are professional antigen presenting cells
that have the capacity to generate innate and adaptive immune
responses, and are essential to induce immunity against cancer [4].
DC migrate from peripheral blood to different organs and tissues
wherein they capture antigens and process them to form MHC-II-
peptide complexes. This non-activated (immature) DC can present
self-antigens to T cells, which leads to immune tolerance either
through T cell deletion or through the differentiation of regulatory
or suppressor T cells [5]. By contrast, activated (mature) antigen-
loaded DC, which express some specific molecules such as CD40,
CD80 and CD86, can launch the differentiation of antigen-specific
T cells into effect tor T cells with unique functions and cytokine
pro-files [6]. The use of mature DC to prime responses to tumor
associated antigens (TAA) provides a promising approach for
cancer immunotherapy, but clinically relevant responses have
been rather poor until now [7].
Issues regarding the optimal dose and route of administration
for DC vaccination used in cancer therapy remain to be addressed.
In fact, only a small proportion of DC intradermally injected
reaches the draining lymph nodes [8,9]. We have previously
demonstrated both in vivo and in vitro that DC pre-conditioning
with low molecular weight hyaluronan (LMW HA) is able to
enhance DC migration toward regional lymph nodes in mice [10].
This effect was shown to be independent of two of the HA
receptors, CD44 and TLR4, and to be likely mediated, at least
partially, by an increased CCR7 expression [11]. CCR7 is a key
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molecule which interacts with the chemokines CCL19 and CCL21
and it was found to be crucial for guiding DC migration from
peripheral tissues to draining lymph nodes [12–14].
A number of cytokines and factors have been used as culture
medium supplement in order to increase such migratory capacity
in DC, including PGE2 and the TLR3 agonist Poly (I:C) [15].
However, these compounds might also induce the expression of
IDO (indoleamine-2,3-dioxygenase) and thereby would eventually
suppress immune responses or generate tolerogenic DC [15,16]. In
addition, it has been observed that poly (I:C) and LPS can affect
the maturation process of peripheral blood monocytes by inducing
the so-called suppressors of cytokine signaling (SOCS) activation
[17,18].
Tumors induce immunosuppression by secreting different
cytokines and immunosuppressive molecules which finally inter-
fere with approaches aimed at generating anti-cancer immunity
[19]. Among them, IL-8 is a chemokine produced in large
amounts by the majority of tumors [20]. IL-8 has been implicated
in the resistance to antiangiogenic therapies [21] and in the failure
of DC-based immunotherapy protocols [22]. In fact, DC can
produce and respond to IL-8, a molecule shown to inhibit anti-
tumor immune responses when it was peri/intra-tumoraly injected
[23].
Hyaluronic acid (HA) is a lineal, large and ubiquitous
glycosaminoglycan with a simple chemical structure found mainly
in tissues undergoing cell proliferation, regeneration and repair
[24]. HA functions are well known to be size-dependent and the
LMW HA form has been shown to induce the expression of pro-
inflammatory genes such as IL-8, IL-12, TNF-a and inducible NO
synthase in many types of cells including DC [25,26]. In addition,
LMW HA or its small fragments were shown to stimulate T cell
responses by activating and up-regulating co-stimulatory mole-
cules on DC in a CD44-independent and TLR4-dependent
manner [27,28]. Moreover, it has also been demonstrated that
LMW HA can act as an adjuvant promoting antigen-specific T
cell responses in vivo through TLR2 stimulation [29].
The aim of this work was to evaluate the effects of LMW HA
pre-conditioning on tumor-pulsed human DC obtained from both
healthy donors (HD) and CRC patients. We found that LMW HA
induced DC/TL maturation state able to enhance lymphocyte
proliferation, and most importantly increasing their migratory
capacity and avoiding tumor tissue attraction. These results
provide the rationale for the potential use of LMW HA as an
immunostimulatory molecule for DC-based vaccines protocols in
the treatment of cancer patients.
Materials and Methods
Reagents
Pharmaceutical endotoxin-free LMW HA of definite size (1–
36105 Da) from CPN spol.s.r.o (Czech Republic) was supplied by
Farmatrade (Buenos Aires, Argentina). A stock solution of 5 mg/
ml LMW HA was prepared, and the presence of endotoxins was
determined by Limulus amebocyte lysate (LAL) assays with a
sensitivity limit of 0.05–0.1 endotoxin units (EU) per ml (Sigma–
Aldrich). GM-CSF was obtained from PrepoTech or Bioprofarma;
CCL21, from PeproTech, and IL-4 and Poly (I:C), from
Invitrogen.
Blood and tumor tissue
CRC patients and HD were recruited in the study after signing
informed consent forms. Peripheral blood sample and colorectal
carcinoma tissue were obtained at the time of surgical resection at
the Austral University Hospital. Informed consent was obtained
from all patients in accordance with our IRB.
Generation of dendritic cells
Peripheral blood mononuclear cells (PBMC) were isolated by
Ficoll-Paque gradient. Cells were plated into 6-well plates for 2 h.
Then, adhered cells were subsequently cultured for up to 7 days in
RPMI 1640 medium (Invitrogen), containing 10% fetal calf serum
(Invitrogen), 2 mM L-glutamine, 100 U/mL penicillin, 100 mg/
ml streptomycin, human recombinant GM-CSF (Bioprofarma,
Growgen, 350 ng/ml), human recombinant IL-4 (IL-4 R&D
Systems 500 UI/ml) and 2-bMercaptoethanol (0.05 M). In HA
stimulation experiments, cells were treated from day 3 with LMW
HA (50 mg/ml). At day 7, DC were pulsed with autologous tumor
lysates (200 mg/106 cells/ml) for 12–18 h, with or without LMW
HA (50 mg/ml). Poly (I:C) (10 mg/ml) treatment was used for DC
activation and as another control condition. Cells were then
centrifuged and used for experiments.
Tumor lysates
Tumor tissues were frozen at 280uC until use. Then, tumor
samples were dispersed with needle and scalpel and disrupted by 5
freeze-thaw cycles. For large debris removal, tumor lysates were
centrifuged at 300 rpm for 10 min. The supernatant was collected
and passed through a 0.22 mm Millipore Express, sterile, low
binding proteins filter unit. The protein concentration of the lysate
was determined by Bradford assay. The resulting tumor lysates
were aliquoted and stored at 280uC until use.
Flow cytometry
Staining and flow cytometric analyses of generated DC were
carried out using standard procedures. Briefly, cells were stained
with different conjugated antibodies as follows: anti-CD11c (B-
ly6), anti-MHC-II (G46-6), anti-CD40 (5C3), anti-CD80 (L307.4),
anti-CD86 (2331), and their respective isotypes controls (BD
Biosciences, San Diego, CA, USA) on ice for 30 min, washed
thoroughly with PBS-1% BSA. Cells were then fixed with 1%
paraformaldehyde and subjected to flow cytometry (FACSCalibur,
BectonDickinson-BD, USA). Data were analyzed using Cyflogic
software.
Mixed lymphocyte reaction
Tumor-free female Nu/Nu nude mice were intraperitoneally
injected with 1.56106 DC/TL pre-treated or not with LMW HA,
and with allogeneic healthy human-derived CFSE-labeled PBLs
(56106). Forty eight hours later, cells were obtained by intraper-
itoneal lavages and incubated with mouse anti-human CD3
antibody for 30 min. They were subsequently incubated with
biotinylated anti-mouse antibody and avidin-Texas Red for
45 min. Samples were analyzed using a FACSCalibur Flow
Cytometer (Becton Dickinson). For FACS analysis lymphocytes
were gated based on CD3+ marks and the number of T cell
divisions was measured as proportional to the dilution of CFSE
intensity.
Lymph node and tumor conditioned medium generation
Tumoral tissues were obtained from Nu/Nu nude mice carrying
human s.c. implanted CRC fresh fragments. Mice were sacrificed;
lymph node and tumor tissue were removed and minced into
pieces smaller than 1 mm3. To obtain lymph node (LNCM) and
tumor conditioned medium (TCM), the minced fragments were
transferred into a 24 well tissue culture plate (6 fragments/well)
with 500 mL of DMEM (plus 2 mmol/L glutamine, 100 U/mL
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penicillin and 100 mg/mL streptomycin) with 0.05% BSA but
without FBS. The supernatant was collected 24 h later and stored
at –80uC until use.
In vitro migration assays
For in vitro migration assays, micro-chemotaxis Boyden
Chamber units were used. DC/TL (1,5–2,56104) treated or not
with LMW HA (50 mg/ml) or Poly (I:C) (10 mg/ml) were placed
into the upper chamber of the transwell unit. In some assays DC/
TL treated or not with LMW HA were preincubated for 24 h with
an IL-8 neutralizing antibody (20 mg/ml). Chemoattractant
medium containing 100 ng/ml of CCL21, LNCM, TCM, human
recombinant IL-8 (20 ng/ml) or DMEM as negative control was
placed in the lower chamber of the transwell unit. In blocking
assays neutralizing IL-8 or isotype antibody (20 mg/ml) was added
to TCM. The system was incubated for 4 h at 37uC in a 5% CO2
humidified atmosphere. Cells which migrated through the
membrane pores were stained with DAPI and counted using
UV microscopy with a 10x objective lens: 5 fields per well were
analyzed and the mean number of cells/field 6 SEM were
calculated. Results are shown as DC/TL and DC/TL/LMW HA
migration index. Poly (I:C) was used as a positive control
maturation stimulus.
Zymography
Metalloproteinase activity was determined by zymography.
Supernatant of culture from DC/TL treated or not with LMW
HA was run on a 10% SDS PAGE containing 0.1% gelatin
(Sigma-Aldrich). The gel was stained with Coomassie Brilliant
Blue R-250 for 30 min at room temperature. Gelatinase activity
was visualized by negative staining; gel images were obtained with
a digital camera (Canon EOS 5D), and were subjected to
densitometric analysis using Scion Image software (Scion Corpo-
ration, Frederick, MD). Relative MMP-2 activity was obtained by
normalizing values to untreated samples (DC/TL). HT1080 cell
line supernatant was used as positive control of MMP-2 and
MMP-9 activity [30].
qPCR
Total RNA from DC/TL treated or not with LMW HA was
extracted by Tri Reagent (Sigma-Aldrich Co., St. Louis MO,
USA). Two micrograms of RNA were reverse transcribed with
200 U of SuperScript II Reverse Transcriptase (Invitrogen,
Carlsbad, CA, USA) and 500 ng of Oligo (dT) primers. cDNAs
were subjected to real time PCR. Each 25 ml reaction volume
contained 1 unit Taq DNA polymerase (Invitrogen), 16 PCR
reaction buffer (20 mM Tris-HCl, pH 8.4, and 50 mM KCl),
1.5 mM Mg2Cl, 200 mM of dNTPs and 0.4 mM of each specific
primer: TLR2 forward 59-GGGTTGAAGCACTGGACAAT-39
and reverse 59-CTGCCCTTGCAGATACCATT-39; TLR4 for-
ward 59-TGAGCAGTCGTGCTGGTATC-39 and reverse 59-
CAGGGCTTTTCTGAGTCGTC-39; CD44 forward 59-
GCGCAGATCGATTTGAATTAA-39 and reverse 59-
GTGCCCTTCTATGAACCCAT-39; IL-8 forward 59-
GGTGCAGTTTTGCCAAGGAG-39 and reverse 59-
TTCCTTGGGGTCCAGACAGA-39; CXCR1 forward 59-
TTTTCCGCCAGGCTTACCAT-39 and reverse 59- AACAC-
CATCCGCCATTTTGC-39; CXCR2 forward 59- TAAGTG-
GAGCCCCGTGGGG-39 and reverse 59- TGGGCTCAGGGG-
CAGGATG-39. PCR conditions were: 90 seconds at 94uC and
then 40 cycles of 30 seconds at 94uC, 30 seconds at 60uC and
30 seconds at 72uC. Values were normalized to levels of
glyceraldehyde-3-phosphate dehydrogenase (GAPDH; used as
housekeeping) transcript (forward 59-
CATCTCTGCCCCCTCTGCTG-39 and reverse 59-
GCCTGCTTCACCACCTTCTTG-39). cDNA was quantified
using the OligoGreen Single Stranded Quantification kit (Invitro-
gen) according to the manufacturer’s instructions. Data were
processed by the DDCt method. The relative amount of the PCR
product amplified from untreated cells was set as 1. A non-
template control (NTC) was run in every assay, and all
determinations were performed as triplicates in three separated
experiments.
Tumor tissue cytokine array
Tumor conditioned medium was obtained as previously
described and detection of human chemokines was performed
using Human Chemokine Antibody Array C1 (RayBio C-Series)
according to the manufacturer’s instructions. The chemokines
analyzed were: BLC, CCL28, CCL23, CTACK, CXCL16, EN78,
Eotaxin1, Eotaxin2, Eotaxin3, Fractalkine, GCP2, GRO, GROa,
HCC4, I-309, I-TAC, IL-8, IP-10, XCL1, MCP-1, MCP-2,
MCP-3, MCP-4, MDC, MIG, MIP-1a, MIP-1b, MIP-1d, MIP-
3a, MIP-3b, MPIF1, NAP2, PARC, RANTES, SDF-1a, SDF-1b,
TARC, TECK.
In vivo migration assays
DC/TL treated or not with LMW HA and stained with CM-Dil
were inoculated subcutaneously into the back of nude mice,
between tumor and nearest lymph node, after 72 h of s.c. tumor
implantation. At 48 h mice were sacrificed and tumor and
ipsilateral inguinal lymph nodes were removed, dissected and
dissociated by enzymatic digestion with D-collagenase (Cabio-
chem). Red blood cells were removed using a lysis solution (0.15 M
NH4Cl, 1 mM KHCO3, 0.1 Na2-EDTA). The remnant cells were
subsequently fixed in 1% paraformaldehyde and subjected to flow
cytometric analysis (FACSCalibur, Becton–Dickinson, BD). Data
were processed using Cyflogic software.
Ethics statement
Human cells and tumor tissues were obtained from healthy
donors/patients after written informed consent and protocol were
approved by the ‘‘Institutional Evaluation Committee’’ (CIE) from
School of Biomedical Sciences, Austral University (Protocol
No. 12-019). Animals were maintained at our Animal Resource
Facilities (School of Biomedical Sciences, Austral University) in
accordance with the experimental ethical committee and the NIH
guidelines on the ethical use of animals. The ‘‘Animal Care
Committee’’ from School of Biomedical Sciences, Austral
University, approved the experimental protocol. All surgery was
performed under isoflurane anesthesia, and all efforts were made
to minimize suffering.
Statistical analysis
Paired t test or Mann–Whitney (InStat, GraphPad Software)
were used for statistical analyses. Differences with p values #0.05
were considered as statistically significant.
Results
Patient characteristics and dendritic cells generation
Fifteen HD and 25 CRC patients were recruited in this study.
Nineteen patients had liver metastasis and 39% had received
previous chemotherapy. DC were generated from PBMC. DC
were co-cultured with autologous tumor lysates (TL) at day 6 for
18 h. In HA condition, LMW HA (50 mg/ml) was added to the
culture medium (see Materials and Methods). At day 6, cultured
DC displayed a relatively immature phenotype but became more
Dendritic Cells Migration and Hyaluronan
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mature when they were pulsed with autologous TL. When CD11+
DC/TL were gated we evidenced that LMW HA pre-incubation
induced a statistically significant up-regulation of MHC-II and
CD86 expression in HD DC (p#0.05) (table 1).
Dendritic cells are potent stimulators in mixed
lymphocyte reaction after LMW HA stimulation
We then asked whether LMW HA treatment would impact on
DC antigen presentation. To this end we performed an in vivo
MLR assay using allogeneic CFSE-labeled PBL from HD and
LMW HA primed/non-primed DC/TL which were injected
inside nude mice peritoneal cavity as previously described [23]. As
a result, a 72% and 80% increase in PBL proliferation activity was
observed in the LMW HA primed DC/TL (DC/TL/LMW HA)
condition when compared to LMW HA non-primed DC/TL
(DC/TL) one in HD or CRC patients, respectively (p#0,05)
(Fig. 1, b).
LMW HA treatment increases migratory response of DC
toward CCL21 and induces their CCR7 expression
The process of DC migration is insufficiently understood [31].
Once DC capture tumor antigens, DC acquire the ability to cross
through the endothelium and to migrate through the extracellular
matrix and thereby entering the lymph node inner cortex [32–34].
Indeed, it is well known that both lymph nodes and tumors secrete
several cytokines which might attract DC [22]. To further
understand mechanisms involved in LMW HA effects on DC we
analyzed the CCL21/CCR7 axis and found an increased ability to
migrate toward CCL21 in DC/TL/LMW HA in vitro when
compared to DC/TL condition, in both HD or CRC patients
(38% and 25%, respectively; p#0,01) (Fig. 2, a). In addition,
treatment with LMW HA upregulated the expression levels of
CCR7 in DC (HD DC fold change 2,7; and CRC patients DC
fold change 3,6; p#0,05) (Fig. 2, b).
LMW HA treatment increase DC migratory capacity
toward lymph node supernatant
Migration of DC to lymph node allows their interaction with
naı¨ve T cells, a critical step in the induction of immunity against
cancer and a challenge for DC-based vaccine protocols [10].
Therefore, we decided to mimic in vitro the conditions faced by
DC when they are inoculated in vivo by using lymph node
conditioned medium (LNCM) as a chemoattractant. Interestingly,
a potent migration of DC toward LNCM was found when they
were pre-incubated with LMW HA in comparison with DC/TL
condition. In contrast, poly I:C induced migration of DC only
when they derive from HD (Fig. 2, c).
LMW HA priming of DC reduces their migratory response
to IL-8 and inhibited their attraction to tumor
conditioned medium
It was recently described that DC IL-8 pre-exposure abrogated
DC tumor attraction [23]. We found that LMW HA treatment up-
regulated IL-8 expression in DC/TL (Fig. 3, a). Thus, to study
whether LMW HA pre-conditioned DC might decrease their
response to tumor-derived signals we decided to analyze the IL-8/
CXCR axis. After the confirmation of IL-8 expression in tumor
conditioned medium (TCM) by a cytokine array assay performed
to explore changes in the profile of chemokines secreted by tumors
(Fig. 3, b) we observed that only LMW HA pre-treatment
decreased by 50% the fraction of DC that migrated toward
human recombinant IL-8 (Fig. 4, a). It is worth noting that a
reduce migration of DC towards TCM was only observed in DC/
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Figure 1. LMW HA treatment of DC enhances human T-cell proliferation in vivo. Nude mice received intraperitoneal injections of human-
derived CFSE-labeled PBLs (56106) and allogeneic mature DC/TL, or DC/TL/LMW HA (1,56106). Proliferation was monitored 48 h later by FACS-gated
lymphocytes from peritoneal lavages by quantifying fluorescent dye signal which is inversely correlated to their proliferation rate. Fluorescence
intensity in the input undivided lymphocytes was over 95% (gray line in the histogram). a) Three histograms representative of both HD and CRC
patients are shown. Gray line: undivided lymphocytes; gray shadow: Lymphocytes + DC/TL; black line: Lymphocytes + DC/TL/LMW HA. b) Bars
represent percentage of lymphocyte proliferation increase 6 SEM respect to undivided lymphocytes (HD n: 5 and CRC patients n: 5). White bar:
lymphocyte alone; gray bar: DC/TL; black bar: DC/TL/LMW HA. *DC/TL vs DC/TL/LMW HA; Paired t test; p#0.05.
doi:10.1371/journal.pone.0107944.g001
Figure 2. LMW HA treatment increases migratory response of DC toward CCL21 inducing their CCR7 expression and increases their
migratory response toward lymph node supernatant. a) Migratory ability of DC treated or not with LMW HA toward CCR7 ligand CCL21
(200 ng/ml) was evaluated in a Boyden chamber system. DC were loaded into the upper well of the chamber and CCL21 was added to the lower
chamber. Data are expressed as DC/TL and DC/TL/LMW HA migration index. Poly (I:C) was used as a positive control of maturation stimulus. b) CCR7
expression was examined by qPCR. Black bars represent CCR7 fold-change expression in comparison with DC/TL. c) Similar chemotaxis assays were
set up placing lymph node supernatant from tumor bearing nude mice in the lower chamber as chemoattractant. Bars represent DC migration index
from both HD and CRC patients. Gray bar: DC/TL; black bar: DC/TL/LMW HA; white bar: DC/TL/Poly (I:C). DC/TL vs DC/TL/LMW HA. Mann Whitney t
test; * p#0.05; **p#0.01.
doi:10.1371/journal.pone.0107944.g002
Dendritic Cells Migration and Hyaluronan
PLOS ONE | www.plosone.org 5 September 2014 | Volume 9 | Issue 9 | e107944
TL/LMW HA experimental group when compared to DC/TL
control (Fig. 4, b). Moreover, when IL-8 was blocked with an anti-
IL-8 mAb a 40% reduction in DC migratory response to TCM
was observed in DC/TL or DC/TL/Poly (I:C) conditions, while
no changes were observed on DC/TL/LMW HA group (Fig. 4,
b). These in vitro results suggest the possibility that IL-8 is
important for DC attraction toward tumors and that LMW HA
pre-treatment may ameliorate this effect.
Pre-treatment with LMW HA induces metalloproteinase
activity and modulates the expression of HA receptors in
DC
Considering that metalloproteinases (MMPs) participate in DC
migration through the ECM [35] we further evaluated if LMW
HA might affect DC/TL MMP’s activity by zymography. Indeed,
pre-incubation of DC with LMW HA resulted in a 30% increase
in the gelatinolytic activity when compared to control (Fig. 5, a).
HA is a component of the ECM with the capacity to induce cell
signaling mechanisms on cells through several receptors such as
CD44 [36], TLR-2 [29], and TLR-4 [37]. These receptors have
been implicated in DC maturation as well in adhesion and
migration processes. To further study the effects of LMW HA on
DC/TL we analyzed its impact on HA receptors expression by
qRT-PCR. Interestingly, a down-regulation of the HA receptors
CD44, TLR-2, and TLR-4 was found in DC/TL/LMW HA
derived from HD and CRC patients when compared to DC/TL
control group (Fig. 5, b).
DC pre-incubated with LMW HA show increased in vivo
migration capacity towards lymph node
We have previously reported that bone marrow-derived DC/
TL pre-incubated with LMW HA show a higher capability to
migrate toward regional lymph node once they were inoculated
subcutaneously in a murine model of CRC [11]. Based on that, we
aimed at analyzing this feature in PBMC-derived human DC
obtained from HD and CRC patients. For this purpose, we chose
a nude mouse xenograft model based on generating tumors from
human CRC samples. DC/TL treated or not with LMW HA and
stained with CMDil were subcutaneously inoculated in mice in a
region between the tumor and regional lymph node. As shown in
Fig. 6 and when compared to DC/TL, DC/TL/LMW HA from
HD and CRC patients migrated more efficiently toward regional
lymph nodes but were less attracted to tumors (lymph node: HD
4606253 vs. 7036229 cells, CRC 202632 vs. 4696120 cells;
tumor: HD 608681 vs. 193612 cells; CRC 1162665 vs.
6466105 cells; DC/TL vs. DC/TL/LMW HA, respectively).
Discussion
A number of strategies for cancer immunotherapy are currently
under preclinical and clinical evaluation [38]. Activation and
stimulation of DC migration are key steps for the induction of a
potent and specific antitumor T cell response. To date, several
DC-based cancer vaccination strategies have been employed in the
clinic with limited success [39–41]; although in 2010 the FDA
approved the first antigen presenting cell therapeutic cancer
vaccine to prolong survival of patients with advanced hormone-
refractory prostate cancer [42]. Different ‘‘cocktails’’ containing
cytokines, growth factors and other compounds have been used for
maturation and activation of DC including IL-1b, IL-6, TNF,
IFN-a, IFN-c, PGE2 and Poly(I:C) [43,44]. Our previous results
showed that pre-incubation of DC with LMW HA was able to
induce an efficient antitumoral effect in a CRC mouse model
which was found to be mediated by the stimulation of DC
maturation and activation, as well as by the induction of a potent
migratory capacity towards lymphoid areas in vitro and in vivo
[11]. In the present study we demonstrated that LMW HA
represents a potent stimulator of migration toward lymph node for
human DC obtained from both HD and CRC patients, likely
partially involving CCR7/CCL21 axis and inducing resistance to
IL-8, a tumor-derived DC chemoattractant. In addition, LMW
HA treatment enhanced MLR-stimulating capacity of DC in an
in vivo assay. Thus, this work adds new data regarding the ability
of LMW HA to improve migratory capacity of DC that could be
relevant in future design of potential cancer vaccines protocols.
Different studies showed that oligosaccharides of HA, but not
high molecular weight (HMW) HA, can be used to stimulate
immune responses involving DC activation [27,29,45,46]. Never-
theless, this is the first report addressing LMW HA effects on DC
derived from patients with cancer and on their migratory response
to lymph node signals. As expected, DC/TL from HD showed
higher expression levels of maturation markers than those
obtained from CRC patients. LMW HA was able to induce
stimulatory effects on DC promoting an up-regulation of MHC-II
and the co-stimulatory molecule CD86 when obtained from HD
Figure 3. IL-8 expression is upregulated in LMWHA treated DC and is present in tumor supernatant. a) IL-8 expression was evaluated by
qPCR. b) Human chemokine antibody array (38 proteins) was performed from tumor culture supernatant. The signal intensity for each antigen-
specific antibody spot is proportional to the relative concentration of the antigen in the sample. Gray bars: DC/LT; black bars: DC/TL/LMW HA. Mann
Whitney t test; *p#0,05. * vs. DC/TL.
doi:10.1371/journal.pone.0107944.g003
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samples but not in those from CRC patients. This result could be,
at least in part, due to the immunosuppressive state of cancer
patients [47,48]. However, both groups of DC have the capacity to
induce alloreactivity of human lymphocytes in a MLR model. In
addition, LMW HA treatment was found to induce a down-
regulation of TLR-2 and TLR-4 in both HD volunteers and CRC
patients. These receptors belong to a large family of membrane
proteins with cytoplasmic signaling domains and extracellular
domains capable of recognizing pathogen-associated molecular
patterns (PAMPs). Segal et al. have followed the expression of
these molecules during the differentiation process of monocytes to
activated dendritic cells. Down-regulation of these receptors might
Figure 4. LMW HA induces resistance in human DC to IL-8 chemoattraction. a) Chemotaxis assays were set up placing IL-8 in the lower
chamber and LMW HA treated or untreated DC were placed in the upper chamber. b) A similar migration assay was set up placing TCM with addition
of a specific antibody against IL-8 (mAbIL-8) or isotype antibody (20 mg/ml) in the bottom chamber as chemoattractant. Graphs represent data from 4
independent experiments similarly performed expressed as migration index respect to DC/TL migration toward TCM; five fields were counted for
each quadruplicate well. Gray bars: DC/LT; black bars: DC/TL/LMW HA; white bars: DC/TL/Poly (I:C). Mann Whitney t test; *p#0,05; ***p#0,001. * vs.
DC/TL.
doi:10.1371/journal.pone.0107944.g004
Figure 5. DC pre-treated with LMW HA induces MMP activity and downregulates HA receptors expression. a) MMP activity was
analyzed by zymography and quantified by densitometry. Relative MMP activity was obtained by normalizing values to untreated samples (DC/TL).
Bars represent MMP activity from HD. b) qPCR of HA receptors was performed. The results are expressed as fold change related to DC/TL. Gray bar:
DC/TL; black bar: DC/TL/LMW HA. DC/TL vs DC/TL/LMW HA. Mann Whitney t test; *p#0,05; ***p#0,001.
doi:10.1371/journal.pone.0107944.g005
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suggest a mature DC phenotype as it was demonstrated in LPS
stimulated DC [49]. Therefore, it seems that LMW HA has a
stimulatory effect on DC pulsed with tumor lysate in both HD and
CRC patients.
Clinical application of DC-based cancer vaccines has been
limited due to their weak efficacy. One limitation might be related
to the failure of DC to reach secondary lymphoid organs. It is
known that only a small percentage of inoculated DC migrate
toward the lymph nodes where they could activate naı¨ve T cells
[8,50,51]. Once DC are inoculated they undergo a kind of
conflicting force attraction between tumoral- and lymphoid-
derived chemokines. This contrary stimulus and the specific
repertoire receptors expressed by DC determine whether they
would migrate to the lymph node (for antigenic presentation and
lymphocyte activation) or to tumors. It has been shown that
different DC maturation stimuli such as IL1b, TNF-a, PGE2 or
poly (I:C) induce the expression of CCR7 which enhances DC
migration response toward lymph node. However, those molecules
might exert a negative effect on DC in different ways [52]. For
example, it was shown that PGE2 and Poly (I:C) can induce a
tolerogenic state on DC [16]. Moreover, some studies reported
that LPS and poly (I:C) can induce inhibitory effects on DC by
activation SOCS signals [17,18]. We have herein shown in vitro
evidences that LMW HA pre-conditioning enhances DC migra-
tion to CCL21 and inhibits their attraction toward IL-8. Despite it
is likely that many molecules involved in DC migration do not
cross-react across species differences, we demonstrated in vitro
and in vivo that DC/TL/LMW HA increase their migration
toward LNCM from tumor bearing mice and lymph node,
respectively. In addition their attraction to TCM and tumor tissue
was also diminished. These phenomena seem to be at least
partially mediated by upregulation of CCR7 expression levels,
which is the main receptor of CCL19 and CCL21. This cytokine is
expressed by lymphatic endothelial and lymph node stromal cells,
and was shown essential to attract DC toward them [12–14].
Another mechanism that might affect DC recruitment toward
the lymph node is the capacity to digest extracellular matrix by
MMPs, thus facilitating migration through connective tissues and
crossing basement membranes [35]. MMPs also act cleaving cell
surface receptors or their ligands, promoting migration by
releasing or activating ligands for receptors that control cell
motility, or suppressing migration by inactivating chemokines
[53]. In line with this, Ratzinger et al. demonstrated that MMP-2
and MMP-9 are involved in the emigration of DC from epidermal
skin explants as well as dermal DC from the dermis [35]. In
addition, it was previously shown in DC derived from healthy
Figure 6. Pre-incubation of DC with LMW HA increases their migration toward lymph node and reduces their tumor attraction
in vivo. DC/TL were or not LMW HA treated, and after CM DiL labeling were inoculated s.c. in human-tumor bearing nude mice. Twenty four hours
later lymph nodes (a) and tumors (b) were surgically removed and a cell suspension was obtained from these tissues. Number of fluorescent DC was
counted by flow cytometry. The upper panel (a) shows DC/TL migration toward lymph nodes. The lower panel shows migration toward tumor tissue
(b). Bars represent the number of migrated DC per individual HD (1–6) and CRC patients (P 1–4). Gray bar: DC/TL; black bar: DC/TL/LMW HA. * DC/TL
vs DC/TL/LMW HA. Paired t test; *p#0,05.
doi:10.1371/journal.pone.0107944.g006
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volunteers [27] as well as in macrophages [54] and in tumor cell
lines [55], that HA-oligosaccharide but not HMW HA up-
regulates the activity of these MMPs through TLR-4 activation
and by promoting CD44-EGFR interaction enhancing Akt
signaling and cell migration events [56]. We herein showed that
LMW HA was able to induce MMP activity in DC derived from
healthy volunteers.
It is well established that HA size is critical for HA function. In
fact, only HA fragments induce inflammatory cytokines in
different cell types [57]. For this reason we used LMW HA of
defined size (1236105 Da) in our experiments. LMW HA can act
through several known receptors such as CD44, TLR2 and TLR4
which are expressed on immune cells such as monocytes and DC
[37,58]. CD44 is the major cell surface receptor for HA and has
an important role in cell adhesion and migration [59]. We found
that LMW HA treatment inhibited the expression of this receptor
in DC/TL. Nevertheless, CD44 down-regulation not only did not
impair cell migration but also might instead help DC detachment
from ECM and migration through interstitial tissue. Indeed, we
have found that bone marrow derived DC from both wild type
and CD44-deficient mice have a comparable capacity to migrate
to CCL21 in vitro [11]. Moreover, it was also shown that CD44
deficient mice exhibited an improvement of epidermal LC
migration to LNs after epicutaneous sensitization with protein
antigen and, additionally, they showed stronger predominant Th
responses after immunization [60].
Another key finding of this study was that LMW HA induced
the expression of IL-8 in DC/TL. Enhanced IL-8 expression in
response to HA fragments has previously been described in several
cellular types such as endothelial [37], epithelial [61] and cancer
cells [62]. IL-8 is a pro-inflammatory cytokine present at large
amount in cancer microenvironment and, noteworthy, involved in
cell migration process. In fact, transcription of both IL-8 and
MMP-2 has been reported to be regulated through NFkb [63]
which in turn is activated by HA [62]. Luca et al. evidenced that
IL-8 affects DC migratory capacity by increasing MMP-2
expression [64]. In addition, IL-8 acts in an autocrine and
paracrine fashion on melanoma cells causing their enhanced
migratory capacity [65]. Furthermore, it was described that pre-
exposure to IL-8 results in desensitization of the DC to the
chemotactic effects of IL-8. This effect is relevant taking into
account the large production of this molecule by tumor cell and
their critical role in DC intratumoral retention [22]. It is important
to emphasize that IL-8 was found not being able to modify neither
DC maturation nor CXCR1 and CXCR2 expression [22,23].
Altogether, these effects could explain, at least in part, both the
higher DC migration into LNs and the lower attraction to tumor
tissue without impairment in their immunologic status.
Finally, this study showed for the first time that LMW HA -a
highly conserved and poorly immunogenic molecule- represents a
promising candidate to be used in DC maturation protocols in
order to increase their activation status as well as to improve their
migratory capacity toward lymph nodes and inhibited their
recruitment into tumors.
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